Larimar Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2040
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 6, 2027The maintenance fee for Molecules for Organelle-Specific Protein Delivery (US 11,891,420) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Methods for Treating Myelin Associated Diseases and Mitochondria Associated Diseases (US 11,976,100) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,411,145 | Methods for quantifying frataxin activity In force · From the USPTO record | In force | From the USPTO record | |
| US 12,091,437 | Molecules for Organelle-Specific Protein Delivery In force · High confidence | In force | High confidence | |
| US 12,351,611 | Molecules for Organelle-Specific Protein Delivery In force · High confidence | In force | High confidence | |
| US 11,976,100 | Methods for Treating Myelin Associated Diseases and Mitochondria Associated Diseases In force · High confidence | In force | High confidence | |
| US 12,790,374 | Methods for Treating Myelin Associated Diseases and Mitochondria Associated Diseases In force · High confidence | In force | High confidence | |
| US 11,891,420 | Molecules for Organelle-Specific Protein Delivery In force · High confidence | In force | High confidence | |
| US 11,988,675 | Methods for quantifying frataxin activity In force · From the USPTO record | In force | From the USPTO record | |
| US 12,390,509 | Pharmaceutical Composition Comprising Frataxin Fusion Protein and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,566,178 | Methods of Quantifying Frataxin and Frataxin Fusion Proteins In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending